Form 4: MAIA Biotechnology Director, Cristian Luput, Reports Stock Option Grant

Director Cristian Luput reports acquisition of stock options in MAIA Biotechnology, Inc.

Summary

• On June 30, 2024, Cristian Luput, a director of MAIA Biotechnology, Inc., acquired 5,728 stock options.
• The options were granted pursuant to the company's 2021 Equity Incentive Plan.
• The exercise price of the options is $3.42.
• The options vest immediately and are exercisable from the grant date, expiring on June 30, 2034.
• Following the transaction, Luput directly owns 5,728 derivative securities.

Sentiment

Score: 6

Explanation: The document is a routine disclosure of a stock option grant, which is generally neutral. It indicates that the director has a vested interest in the company's performance.

Positives

• The grant of stock options aligns the director's interests with those of the shareholders.
• Immediate vesting of the options provides an incentive for the director to contribute to the company's success.

Industry Context

Stock option grants are a common practice in the biotechnology industry to incentivize directors and align their interests with shareholders.

Comparison to Industry Standards

• Stock option grants to directors are a standard compensation practice across the biotechnology industry.
• The vesting schedule of 100% on the grant date is more aggressive than some companies, which may use a multi-year vesting schedule.
• Comparing the size of the grant to similar companies and director roles would provide further context.

Stakeholder Impact

• The stock option grant could potentially impact shareholders by diluting equity if the options are exercised.
• The grant incentivizes the director, which could benefit shareholders through improved company performance.

Key Dates